Recent Updates
Recently added Catalysts

Rigel Pharmaceuticals, Inc.

RIGLFDA catalysts, PDUFA dates & pipeline intelligence
$42.92
▼ -0.81 · -1.85%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full RIGL financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $24.9552W HIGH $52.60
Volume
242.20 K
Value Traded
10.35 M
Short % Float
13.93%
Days to Cover
12.9
-3.59%Week
-8.13%1 Month
-8.6%3 Month
+48.92%6 Month
-21.81%5 Year
-95.55%All Time

Cash Data

Unlock RIGL cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
808.18 M
EPS (TTM)
16.31
P/E Ratio
2.63
Ent. Value
708.88 M
Total Shares
18.83 M
Float Shares
18.20 M
Insiders
3.32%
Institutions
96.99%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Phase 1b data presentation
R289
relapsed or refractory lower-risk myelodysplastic syndrome (MDS)
Fast TrackOrphan
Phase 1bSmall MoleculesHematology
Unlock every RIGL catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

RIGL Catalyst Timeline

Dated clinical, regulatory and corporate events for Rigel Pharmaceuticals, Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for Rigel Pharmaceuticals, Inc.

942Total events
11Upcoming
205Tier-1 (high impact)
2009 to 2028Coverage

Upcoming catalysts 2

T2Enrollment Complete
Subscribe to view catalyst details
R289
T2Dose Finding Update
Subscribe to view catalyst details
R289

Event history 50

●Quarterly UpdateCorporate
Rigel reported third quarter 2026 financial results
◆Poster PresentationGAVRETOApprovedPresentation
HRQoL data with pralsetinib in ARROW RET fusion-positive NSCLC ePoster at ESMO 2026
RET fusion-positive NSCLCsource ↗
▲Product LaunchFostamatinibApprovedPost-Market
Knight commercially launched TAVALISSE in Brazil
chronic immune thrombocytopenia (ITP)source ↗
▲FDA ApprovalFostamatinibApprovedFDA Decision
Knight Therapeutics received INVIMA approval for TAVALISSE in Colombia
chronic immune thrombocytopenia (ITP)source ↗
▲Product LaunchVEPPANUApprovedPost-Market
VEPPANU became commercially available in the U.S.
ER+/HER2-, ESR1-mutated advanced or metastatic breast cancersource ↗
▲Product LaunchVEPPANUApprovedPost-Market
VEPPANU now available by prescription in the US
ER+/HER2-, ESR1-mutated advanced or metastatic breast cancersource ↗
●Quarterly UpdateCorporate
Rigel reported Q2 2026 financial results
▲Runway Guidance UpdateCorporate
Increased 2026 total revenues guidance to $285-295M
▲Product LaunchVEPPANUApprovedPost-Market
VEPPANU expected to be commercially available in the U.S.
ER+/HER2-, ESR1-mutated advanced or metastatic breast cancersource ↗
●Enrollment UpdateR289Trial
64 patients enrolled in Phase 1b study of R289 in R/R lower-risk MDS as of July 16, 2026
relapsed or refractory lower-risk myelodysplastic syndrome (MDS)source ↗
Unlock the full RIGL catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How RIGL actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-05-29GAVRETO (pralsetinib) Phase 3 data readout Phase 3
Unlock 14 more RIGL historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
3
Drugs Scored
rNPV / MCap
Top Drug
Top 40%
Micro Cap
(rank 291 of 725)
Percentile Rank
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Sep 2026; product lines: last four quarters to Sep 2026 (10-K and 10-Q))
ProductRevenuePrior periodChange
TAVALISSE
GAVRETO
REZLIDHIA
Showing 14 of 21 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
Olutasidenib Small MoleculesNCT06161974High Grade GliomaPhase 2 RECRUITING 60Jun 1, 2035
Olutasidenib Small MoleculesMarketedNCT06782542Acute Myeloid LeukemiaApproved RECRUITING 16Mar 31, 2029
Olutasidenib Small MoleculesMarketedNCT07471841IDH1 MutationApproved RECRUITING 25Jun 1, 2029
R906289 Monosodium Small MoleculesNCT05308264Low Risk Myelodysplastic SyndromesPhase 1/2 RECRUITING 86Dec 1, 2028
Fostamatinib Small MoleculesMarketedNCT02076399Immune Thrombocytopenic PurpuraApproved COMPLETED 273Apr 21, 2016
Fostamatinib Small MoleculesNCT02612558Warm Antibody Autoimmune Hemolytic AnemiaPhase 3 COMPLETED 206Dec 1, 2019
Fostamatinib Small MoleculesNot countedNCT04629703Covid19Phase 3 COMPLETED 280Sep 5, 2022
Fostamatinib Small MoleculesNot countedNCT00706342Purpura, Thrombocytopenic, IdiopathicPhase 2 COMPLETED 18Apr 1, 2010
R788 Small MoleculesNot countedNCT00326339Rheumatoid ArthritisPhase 2 COMPLETED 189Dec 1, 2007
Fostamatinib Small MoleculesNot countedNCT05040698Hidradenitis SuppurativaPhase 2 COMPLETED 20Jan 27, 2023
Fostamatinib Small MoleculesNot countedNCT00665925Rheumatoid ArthritisPhase 2 COMPLETED 676Jun 1, 2009
Fostamatinib Small MoleculesNot countedNCT02112838IGA NephropathyPhase 2 COMPLETED 76Nov 12, 2018
Fostamatinib Small MoleculesNot countedNCT00446095LymphomaPhase 1/2 COMPLETED 81Oct 1, 2010
Fostamatinib Small MoleculesNot countedNCT00798096T Cell LymphomaPhase 2 COMPLETED 18Apr 1, 2010
Unlock the RIGL pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every RIGL program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
GAVRETO RET fusion-positive cancers2026-10-1953%; 81.3%; 88%; 75%; 26%; 12.2 monthsRead MoreRigel Highlights New GAVRETO® (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026Read More
Scroll for more · summaries link to the source press release
Unlock every RIGL trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock RIGL insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Schorno Dean LOfficer (EVP & Chief Financial Officer)Option 694 79,056 held$12.70 09/02/2026
Unlock the full RIGL insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
SOLEUS CAPITAL MANAGEMENT, L.P. 3.2 % (28 %) 88.76 M 1.84 M
Unlock every fund holding RIGL
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in RIGL
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see RIGL ownership
Insider and institutional ownership, quarter by quarter.

RIGL Short Interest

Shares sold short, counted twice a month.

13.93%
Short % of Float
of tradable shares sold short
2.5M
Shares Sold Short
-7.2% vs prior count
12.9 Very high
Days to Cover
trading days of normal volume to buy every short share back
196.1K
Avg Daily Volume
the average used for days to cover
Unlock RIGL short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-11-20
Unlock RIGL option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live RIGL option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock RIGL options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How RIGL ranks across every disease it competes in

Competitive Position is a premium feature
See how RIGL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

RIGL News

RIGL
Nov 10, 2026
RIGLConferences/Events

Rigel to Present at the Jefferies Global Healthcare Conference in London

Rigel Pharmaceuticals announced that CEO Raul Rodriguez will present at the Jefferies Global Healthcare Conference in London on November 17, 2026. The presentation will provide an overview of the company, which focuses on therapies for hematologic disorders and cancer. Interested parties can access the live webcast through Rigel's website.

Read more →
RIGL
Nov 5, 2026
RIGLGeneral
▼ -13.3%on this newsshared move

Rigel Reports Third Quarter 2026 Financial Results

Rigel Pharmaceuticals reported third quarter 2026 revenues of $80.9 million, with net product sales of $72.3 million. The newly launched VEPPANU generated $6.6 million in sales. Rigel anticipates selecting the recommended Phase 2 dose for R289 by the end of 2026, with updated data to be presented at the ASH Annual Meeting in December.

Read more →
RIGL
Nov 4, 2026
RIGLPhases

Rigel Announces Oral Presentation of Phase 1b Data for R289 in Patients with Lower-Risk MDS at the 68th American Society of Hematology Annual Meeting and Exposition

Rigel Pharmaceuticals announced an oral presentation of updated Phase 1b data for R289, a dual IRAK1/4 inhibitor, at the upcoming ASH Annual Meeting. The study focuses on patients with relapsed or refractory lower-risk myelodysplastic syndrome (MDS). The presentation will include efficacy data, particularly regarding transfusion dependence reduction, and safety updates.

Read more →
RIGL
Oct 29, 2026
RIGLConferences/Events

Rigel Announces Conference Call and Webcast to Report Third Quarter 2026 Financial Results

Rigel Pharmaceuticals will announce its third quarter 2026 financial results on November 5, 2026. Following the announcement, senior management will host a conference call and webcast to discuss the results and provide a business update. The call will be accessible via phone and online, with a replay available for 90 days.

Read more →
RIGL
Oct 19, 2026
RIGLConferences/Events

Rigel Highlights New GAVRETO® (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026

Rigel Pharmaceuticals presented new data on GAVRETO (pralsetinib) at the ESMO Congress 2026, highlighting its efficacy in treating RET fusion-positive cancers. The pooled analysis from the ARROW and TAPISTRY trials showed a 53% overall response rate in solid tumors. Notably, the drug demonstrated an 81.3% response rate in thyroid cancer and improved quality of life metrics in non-small cell lung cancer patients. These findings support pralsetinib's potential as a first-line therapy.

Read more →
RIGL
Oct 2, 2026
RIGLGeneral

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Rigel Pharmaceuticals, Inc. announced the grant of 35,275 restricted stock units to 18 non-executive employees as part of its Inducement Plan. This initiative, approved by the Compensation Committee, aims to attract new talent in accordance with NASDAQ Listing Rule 5635(c)(4). The stock units will vest over four years, promoting employee retention.

Read more →
RIGL
Sep 2, 2026
RIGLConferences/Events

Rigel to Participate in Upcoming September Investor Conferences

Rigel Pharmaceuticals announced its participation in several investor conferences in September 2026. CFO Dean Schorno will engage in one-on-one meetings and present company overviews at the Citi, Cantor, and H.C. Wainwright conferences. These events aim to foster investor relations and showcase Rigel's advancements in hematologic disorders and cancer treatments.

Read more →
RIGL
Aug 13, 2026
RIGLFDA Updates

Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer

Rigel Pharmaceuticals has announced the availability of VEPPANU (vepdegestrant), the first FDA-approved PROTAC for treating advanced or metastatic breast cancer with specific mutations. This new treatment option is aimed at patients who have progressed after at least one line of endocrine therapy. VEPPANU has shown significant improvement in progression-free survival compared to existing therapies. The drug is now available through specialty pharmacies at a cost of $29,400 for a 30-day supply.

Read more →
RIGL
Aug 4, 2026
RIGLGeneral

Rigel Reports Second Quarter 2026 Financial Results

Rigel Pharmaceuticals reported strong financial results for Q2 2026, with total revenues of $78.7 million, including net product sales of $67 million. The company expanded its commercial portfolio by in-licensing VEPPANU, an FDA-approved PROTAC for breast cancer. Despite a decrease in net income compared to the previous year, Rigel remains on track with its clinical programs, particularly the R289 development in lower-risk MDS.

Read more →
RIGL
Jul 28, 2026
RIGLConferences/Events

Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results

Rigel Pharmaceuticals has announced a conference call and webcast to discuss its second quarter 2026 financial results. The results will be reported after market close on August 4, 2026, followed by a live discussion at 4:30 p.m. ET. The event will be accessible via phone and webcast, with an archive available for 90 days.

Read more →
RIGL
Jul 1, 2026
RIGLGeneral

Rigel Appoints Board Member Alison L. Hannah, M.D. as Chief Medical Officer

Rigel Pharmaceuticals has appointed Dr. Alison L. Hannah as Chief Medical Officer, effective July 1, 2026. Dr. Hannah, who has served on Rigel's Board since 2021, resigns from her board position to take on this executive role. She brings significant experience in oncology and will lead the development of Rigel's pipeline, including investigational therapies for hematologic disorders and cancer.

Read more →
RIGL
Jun 16, 2026
RIGLFDA Updates

Rigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant)

Rigel Pharmaceuticals has finalized a licensing agreement for VEPPANU (vepdegestrant), an FDA-approved treatment for advanced breast cancer. The agreement, effective June 11, 2026, includes a $70 million upfront payment to Arvinas and Pfizer. Rigel plans to make VEPPANU commercially available by August 2026, despite potential risks associated with its use.

Read more →
RIGL
May 27, 2026
RIGLConferences/Events

Rigel to Present at the Jefferies Global Healthcare Conference

Rigel Pharmaceuticals, Inc. will present an overview at the Jefferies Global Healthcare Conference on June 3, 2026. CEO Raul Rodriguez will lead the presentation, showcasing the company's focus on hematologic disorders and cancer. Interested parties can access the live webcast through Rigel's website.

Read more →
RIGL
May 22, 2026
RIGLConferences/Events

Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress

Rigel Pharmaceuticals announced that it will present final data from the Phase 3 AcceleRET-Lung trial for GAVRETO at the 2026 ASCO Annual Meeting. Additionally, the company will showcase further data on pralsetinib and REZLIDHIA at both the ASCO and EHA 2026 Congress. These presentations emphasize Rigel's commitment to enhancing treatment options for patients with hematologic disorders and cancer.

Read more →
RIGL
May 14, 2026
RIGLConferences/Events

Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference

Rigel Pharmaceuticals announced that CFO Dean Schorno will present at the 2026 RBC Capital Markets Global Healthcare Conference. The presentation is scheduled for May 19 at 9:30 a.m. ET in New York. This event reflects Rigel's commitment to engaging with the investment community and discussing its advancements in hematologic disorders and cancer treatments.

Read more →
RIGL
May 12, 2026
RIGLFDA Updates
▲ +12.1%on this news· ran to +23% by day 1shared move

Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer

Rigel Pharmaceuticals has entered an exclusive global licensing agreement with Arvinas and Pfizer to develop and commercialize VEPPANU (vepdegestrant), the first FDA-approved oral PROTAC, targeting advanced or metastatic breast cancer. The drug showed a significant 2.4-fold improvement in progression-free survival compared to the standard treatment, fulvestrant, during the Phase 3 VERITAC-2 trial. Rigel expects VEPPANU to substantially contribute to revenue growth and fill an important gap in treatment for patients with ESR1 mutations who have limited options following endocrine therapy. The agreement is set to close in mid-June 2026, pending regulatory clearance.

Read more →
RIGL
May 5, 2026
RIGLGeneral
▼ -5.1%on this news

Rigel Reports First Quarter 2026 Financial Results

Rigel Pharmaceuticals reported first quarter 2026 total revenues of $58.8 million and net income of $8.7 million. Net product sales rose 26 percent to $54.9 million compared to the prior year period. The company remains on track to complete enrollment in the dose expansion phase of its Phase 1b R289 study by the second half of 2026.

Read more →
RIGL
Apr 28, 2026
RIGLConferences/Events

Rigel Announces Conference Call and Webcast to Report First Quarter 2026 Financial Results

Rigel Pharmaceuticals will announce its first quarter 2026 financial results on May 5, 2026, after market close. Following the announcement, senior management will host a live conference call and webcast at 4:30 p.m. ET to discuss the results and provide a business update. The call will be accessible via phone and webcast, with a replay available for 90 days.

Read more →

About Rigel Pharmaceuticals, Inc.

South San Francisco, CA 174 employees rigel.com
Headquarters611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA, 94080
BIOPHARMAWATCH ELITE
Trade the next RIGL catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime